Search results
Results From The WOW.Com Content Network
lonza.com. Lonza Group AG is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development ...
(Reuters) - Moderna said on Tuesday it will cut production of mRNA drug substance for its COVID-19 vaccine at Lonza's facility in Switzerland this quarter as part of a plan to align manufacturing ...
Lonza Group in Visp where the Moderna COVID-19 vaccine is produced. On 19 December 2020, the Swiss Agency for Therapeutic Products ( Swissmedic ) approved the Pfizer–BioNTech COVID-19 vaccine (Comirnaty) for regular use, two months after receiving the application, although it was expected to give a decision later than other European countries ...
Revenue. US$750 million (2011) [2] Number of employees. 3,600 (2016) [1] Parent. Lonza Group. Website. capsugel.com. Capsugel is a company that manufactures and sells two-piece hard gelatin drug capsules. [3]: 703 Capsugel also sells equipment for filling empty and liquid capsules, as well as equipment for sealing liquid capsules.
Lonza Group Ag (LZAGY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Lonza said on Tuesday it has capacity to fill syringes to serve makers of highly popular new weight-loss drugs in a class known as GLP-1, though it does not produce the active ingredient in those ...
In December 2016, the Lonza Group announced it would acquire Capsugel for $5.5 billion from Kohlberg Kravis Roberts. [146] In February 2017, KKR was reported to be trying to take over the international market research company ARI GfK SE. [147]
Lonza Group has extended a collaboration with a major biopharmaceutical industry client for the supply of an antibody drug conjugate (ADC) against hard-to-treat cancers, the Swiss contract ...